Authosis

Authosis is a biopharmaceutical company focused on developing novel therapeutics that target the autophagy-lysosome pathway to treat inflammatory and respiratory diseases. The company's approach centers on modulating cellular self-cleansing processes to restore homeostasis in tissues affected by chronic stress and aging. Its lead programs are directed toward Chronic Obstructive Pulmonary Disease (COPD) and acute lung injury, conditions where dysfunctional autophagy contributes to disease pathogenesis. Founded by world-renowned experts in pulmonary medicine and autophagy, Authosis utilizes a proprietary screening platform to identify small molecule drug candidates. The company aims to transform the treatment landscape for patients with limited options by addressing the underlying cellular mechanisms of lung degradation. Authosis is backed by strategic investors and maintains strong ties to leading academic medical centers.